FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds specified in cl. 1, and also to a pharmaceutical composition possessing binding activity with respect to Bcl proteins, to applying the declared compounds for preparing a drug for treating cancer and for treating a bcl-mediated disorder.
EFFECT: use of the compounds as Bcl protein inhibitors.
18 cl, 2 tbl, 41 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS AND METHODS OF INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING COMPONENTS | 2005 |
|
RU2416606C2 |
COMPOUNDS AND METHODS OF INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING COMPONENTS | 2006 |
|
RU2424230C2 |
HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
VET PROTEIN DECOMPOSERS | 2017 |
|
RU2752677C2 |
SUBSTITUTED IMIDAZOQUINOLINES | 2018 |
|
RU2768629C2 |
PYRIDOPYRIMIDINONE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2818954C1 |
ALBUMIN-BINDING PRODRUGS BASED ON AURISTATIN E DERIVATIVES | 2018 |
|
RU2795101C2 |
HETEROAROMATIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE MODULATORS | 2014 |
|
RU2672910C9 |
SOLUBLE C5aR ANTAGONISTS | 2017 |
|
RU2748260C2 |
HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
Authors
Dates
2012-05-10—Published
2007-11-14—Filed